Literature DB >> 19244323

Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4.

Jian Zhu1, Gangling Liao, Liang Shan, Jun Zhang, Mei-Ru Chen, Gary S Hayward, S Diane Hayward, Prashant Desai, Heng Zhu.   

Abstract

A conserved family of herpesvirus protein kinases plays a crucial role in herpesvirus DNA replication and virion production. However, despite the fact that these kinases are potential therapeutic targets, no systematic studies have been performed to identify their substrates. We generated an Epstein-Barr virus (EBV) protein array to evaluate the targets of the EBV protein kinase BGLF4. Multiple proteins involved in EBV lytic DNA replication and virion assembly were identified as previously unrecognized substrates for BGLF4, illustrating the broad role played by this protein kinase. Approximately half of the BGLF4 targets were also in vitro substrates for the cellular kinase CDK1/cyclin B. Unexpectedly, EBNA1 was identified as a substrate and binding partner of BGLF4. EBNA1 is essential for replication and maintenance of the episomal EBV genome during latency. BGLF4 did not prevent EBNA1 binding to sites in the EBV latency origin of replication, oriP. Rather, we found that BGLF4 was recruited by EBNA1 to oriP in cells transfected with an oriP vector and BGLF4 and in lytically induced EBV-positive Akata cells. In cells transfected with an oriP vector, the presence of BGLF4 led to more rapid loss of the episomal DNA, and this was dependent on BGLF4 kinase activity. Similarly, expression of doxycycline-inducible BGLF4 in Akata cells led to a reduction in episomal EBV genomes. We propose that BGLF4 contributes to effective EBV lytic cycle progression, not only through phosphorylation of EBV lytic DNA replication and virion proteins, but also by interfering with the EBNA1 replication function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19244323      PMCID: PMC2682057          DOI: 10.1128/JVI.02378-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.

Authors:  Edward Gershburg; Joseph S Pagano
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 2.  Epstein-Barr virus: exploiting the immune system.

Authors:  D A Thorley-Lawson
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

3.  Establishment of an oriP replicon is dependent upon an infrequent, epigenetic event.

Authors:  E R Leight; B Sugden
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

4.  A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro.

Authors:  M R Chen; S J Chang; H Huang; J Y Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo.

Authors:  Lauri L Laichalk; David A Thorley-Lawson
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Epstein-Barr virus-encoded protein kinase BGLF4 mediates hyperphosphorylation of cellular elongation factor 1delta (EF-1delta): EF-1delta is universally modified by conserved protein kinases of herpesviruses in mammalian cells.

Authors:  Kentaro Kato; Yasushi Kawaguchi; Michiko Tanaka; Mie Igarashi; Akihiko Yokoyama; Go Matsuda; Mikiko Kanamori; Kaori Nakajima; Yorihiro Nishimura; Masayuki Shimojima; Hang T T Phung; Eiji Takahashi; Kanji Hirai
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

7.  Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein-Barr virus.

Authors:  B Chaudhuri; H Xu; I Todorov; A Dutta; J L Yates
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

8.  Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors:  Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 9.  Latent and lytic Epstein-Barr virus replication strategies.

Authors:  Tatsuya Tsurumi; Masatoshi Fujita; Ayumi Kudoh
Journal:  Rev Med Virol       Date:  2005 Jan-Feb       Impact factor: 6.989

Review 10.  Origins of bidirectional replication of Epstein-Barr virus: models for understanding mammalian origins of DNA synthesis.

Authors:  Jindong Wang; Bill Sugden
Journal:  J Cell Biochem       Date:  2005-02-01       Impact factor: 4.429

View more
  46 in total

1.  Gammaherpesvirus gene expression and DNA synthesis are facilitated by viral protein kinase and histone variant H2AX.

Authors:  Bryan C Mounce; Fei Chin Tsan; Lindsay Droit; Sarah Kohler; Justin M Reitsma; Lisa A Cirillo; Vera L Tarakanova
Journal:  Virology       Date:  2011-09-22       Impact factor: 3.616

2.  Epstein-Barr virus protein kinase BGLF4 targets the nucleus through interaction with nucleoporins.

Authors:  Chou-Wei Chang; Chung-Pei Lee; Yu-Hao Huang; Pei-Wen Yang; Jiin-Tarng Wang; Mei-Ru Chen
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 3.  Systematic characterization of protein-DNA interactions.

Authors:  Zhi Xie; Shaohui Hu; Jiang Qian; Seth Blackshaw; Heng Zhu
Journal:  Cell Mol Life Sci       Date:  2011-01-05       Impact factor: 9.261

4.  A Human Proteome Array Approach to Identifying Key Host Proteins Targeted by Toxoplasma Kinase ROP18.

Authors:  Zhaoshou Yang; Yongheng Hou; Taofang Hao; Hee-Sool Rho; Jun Wan; Yizhao Luan; Xin Gao; Jianping Yao; Aihua Pan; Zhi Xie; Jiang Qian; Wanqin Liao; Heng Zhu; Xingwang Zhou
Journal:  Mol Cell Proteomics       Date:  2017-01-13       Impact factor: 5.911

5.  Phosphorylation of p27Kip1 by Epstein-Barr virus protein kinase induces its degradation through SCFSkp2 ubiquitin ligase actions during viral lytic replication.

Authors:  Satoko Iwahori; Takayuki Murata; Ayumi Kudoh; Yoshitaka Sato; Sanae Nakayama; Hiroki Isomura; Teru Kanda; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

6.  Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication.

Authors:  Renfeng Li; Jian Zhu; Zhi Xie; Gangling Liao; Jianyong Liu; Mei-Ru Chen; Shaohui Hu; Crystal Woodard; Jimmy Lin; Sean D Taverna; Prashant Desai; Richard F Ambinder; Gary S Hayward; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  Cell Host Microbe       Date:  2011-10-20       Impact factor: 21.023

7.  The Epstein-Barr virus protein kinase BGLF4 and the exonuclease BGLF5 have opposite effects on the regulation of viral protein production.

Authors:  Regina Feederle; Anja M Mehl-Lautscham; Helmut Bannert; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

8.  BGLF4 kinase modulates the structure and transport preference of the nuclear pore complex to facilitate nuclear import of Epstein-Barr virus lytic proteins.

Authors:  Chou-Wei Chang; Chung-Pei Lee; Mei-Tzu Su; Ching-Hwa Tsai; Mei-Ru Chen
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

9.  Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.

Authors:  Christopher B Whitehurst; Marcia K Sanders; Mankit Law; Fu-Zhang Wang; Jie Xiong; Dirk P Dittmer; Joseph S Pagano
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  S-Like-Phase Cyclin-Dependent Kinases Stabilize the Epstein-Barr Virus BDLF4 Protein To Temporally Control Late Gene Transcription.

Authors:  Yoshitaka Sato; Takahiro Watanabe; Chihiro Suzuki; Yuichi Abe; H M Abdullah Al Masud; Tomoki Inagaki; Masahiro Yoshida; Takeshi Suzuki; Fumi Goshima; Jun Adachi; Takeshi Tomonaga; Takayuki Murata; Hiroshi Kimura
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.